雷珠单抗联合视网膜光凝治疗新生血管性青光眼的临床研究  

Application of the intravitreal Ranibizumab combined with retinal photocoagulation for the neovascular glaucoma

作　　者：张分队[1] 郑博[1] 高伟[1] 程燕[1] 吴洁[1] 

机构地区：[1]中国陕西省西安市第一医院眼科,710002

出　　处：《国际眼科杂志》2015年第5期898-899,共2页International Eye Science

摘　　要：目的:探讨雷珠单抗联合视网膜光凝治疗有视功能的新生血管性青光眼的临床疗效。方法:回顾性分析2012-10/2013-09就诊于我院30例36眼有视功能的新生血管性青光眼采用雷珠单抗联合视网膜光凝治疗前及治疗后1wk;1,3mo的视力、眼压、虹膜表面新生血管消退情况及术中、术后并发症。结果:采用雷珠单抗玻璃体腔注射后5d,36眼的虹膜表面新生血管全部消退,平均消退时间3.7±1.4d;治疗前平均眼压30.5±3.6mm Hg,治疗后1wk;1,3mo的平均眼压分别是18.2±2.1,16.8±3.1,17.2±2.4mm Hg,差异具有统计学意义;视力较治疗前无下降或有不同程度提高。术中均无眼内出血,术后无眼内炎等并发症发生。结论:雷珠单抗联合视网膜光凝是治疗有视功能的新生血管性青光眼的一种安全、有效的方法。AIM：To observe the clinical effect of the intravitreal Ranibizumab （ IVR ） combined with retinal photocoagulation for the neovascular glaucoma （ NVG） . METHODS： Clinical data of 30 patients with the neovascular glaucoma （ 36 eyes ） in our hospital from Ocuober 2012 to Sepember 2013 were analyzed retrospectively. All eyes accepted the photocoagulation 7d after lVR （0. 05mL/1. 25mg）. Visual acuity, intraocular pressure （ IOP） , the degradation of iris neovascularization and complications were observed and compared statistically before treatment and 1wk, 1, 3mo after treatment. RESULTS：The new vessels on the iris and the angle of anterior chamber regressed completely in all eyes 5d after lVR, the mean time was 3. 7±1. 4d. The differences were statistically significant when compared IOP （ 18. 2±2. 1, 16. 8 ± 3. 1, 17. 2 ± 2. 4mmHg,） at 1wk, 1, 3mo postoperatively with 30. 5±3. 6mmHg preoperatively. The visual acuity of all the eyes was stable and rose slightly. CONCLUSION： lVB combined with retinal photocoagulation can make the new vessels on the iris and the angle of anterior chamber regression and to lower the IOP. No serious complications were observed after treatment. It is a new security and effective method for neovascular glaucoma.

关 键 词：雷珠单抗玻璃体腔注射 视网膜光凝 新生血管性青光眼 

分 类 号：R774[医药卫生—眼科]